XML 33 R16.htm IDEA: XBRL DOCUMENT
v3.25.1

Investments at equity | 12 Months Ended
--- | ---
Dec. 31, 2024
Equity Method Investments and Joint Ventures [Abstract] |
Investments at equity | 7 Investments at equity Biotherapeutic Solutions Sdn. Bhd. (“BSSB”) – Malaysia The Company owned a 50% interest in Cuprina GHHS LLP, a joint arrangement which was established on July 7, 2022 with GHHS Healthcare Management Sdn, Bhd (“GHHS”). This joint arrangement was principally engaged in wound management services. Subsequently, on February 1, 2023, the joint arrangement has ceased operations following the incorporation and replacement from the new joint venture entity, namely Biotherapeutic Solutions Sdn. Bhd. of which the Company owned a 40% equity interest under the new agreement. On July 11, 2023, the joint venture agreement has been terminated with an immediate effect following the mutual agreement from both parties and the joint venture entity has been closed down accordingly. The parties have agreed that any residual net assets or liabilities from the joint venture entity belong to GHHS. Cuprina MENA Co., Ltd. (“Cuprina MENA”)– Saudi Arabia As of December 31, 2024, the Company owned a 49% equity interest in Cuprina MENA Co., Ltd., an associate which was incorporated on May 21, 2023 with New Future Medical Services Company. This associate is principally engaged in the supply of medical devices and the operation of medical laboratories and supporting medical services. Summarized financial information of the joint venture and associate are set out below: Schedule of financial information of the joint venture and associate
|  | BSSB |  |  | Cuprina MENA |  |  | Total |
|  | S$ |  |  | S$ |  |  | S$ |
As of December 31, 2022 |  |  |  |  |  |  |  |  |  |  |  |
Current assets |  |  | 22,743 |  |  |  | - |  |  |  | 22,743 |
Current liabilities |  |  | 6,670 |  |  |  | - |  |  |  | 6,670 |
For the year ended December 31, 2023 |  |  |  |  |  |  |  |  |  |  |  |
Net sales or gross revenue |  |  | 3,370 |  |  |  | - |  |  |  | 3,370 |
Gross profit |  |  | 2,532 |  |  |  | - |  |  |  | 2,532 |
Net loss |  |  | (14,690 | ) |  |  | - |  |  |  | (14,690 | )
Net loss attributable to the Company |  |  | (7,345 | ) |  |  | - |  |  |  | (7,345 | )
|  | BSSB |  |  | Cuprina MENA |  |  | Total |
|  | S$ |  |  | S$ |  |  | S$ |
As of December 31, 2023 |  |  |  |  |  |  |  |  |  |  |  |
Current assets |  |  | - |  |  |  | 17,580 |  |  |  | 17,580 |
Current liabilities |  |  | - |  |  |  | 35,274 |  |  |  | 35,274 |
For the year ended December 31, 2023 |  |  |  |  |  |  |  |  |  |  |  |
Net loss |  |  | (15,780 | ) |  |  | (52,854 | ) |  |  | (68,364 | )
Net loss attributable to the Company |  |  | (7,890 | ) |  |  | (25,898 | ) |  |  | (33,788 | )
|  | S$ |  |  | S$ |  |  | S$ |  |  | US$ |
|  | BSSB |  |  | Cuprina MENA |  |  | Total |
|  | S$ |  |  | S$ |  |  | S$ |  |  | US$ |
As of December 31, 2024 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Current assets |  |  | - |  |  |  | 9,447 |  |  |  | 9,447 |  |  |  | 6,945 |
Current liabilities |  |  | - |  |  |  | 164,840 |  |  |  | 164,840 |  |  |  | 121,179 |
For the year ended December 31, 2024 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Net loss |  |  | - |  |  |  | (105,981 | ) |  |  | (105,981 | ) |  |  | (77,910 | )
Net loss attributable to the Company |  |  | - |  |  |  | (51,931 | ) |  |  | (51,931 | ) |  |  | (38,176 | )
CUPRINA HOLDINGS (CAYMAN) LIMITED NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

X
- References No definition available. + Details
Name: | us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for equity method investments and joint ventures. Equity method investments are investments that give the investor the ability to exercise significant influence over the operating and financial policies of an investee. Joint ventures are entities owned and operated by a small group of businesses as a separate and specific business or project for the mutual benefit of the members of the group. + References Reference 1: http://www.xbrl.org/2003/role/recommendedDisclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478156/740-323-50-2 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Topic 323 -Publisher FASB -URI https://asc.fasb.org/323/tableOfContent + Details
Name: | us-gaap_EquityMethodInvestmentsDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration